Gilead Sciences (NASDAQ: GILD) recently received a number of ratings updates from brokerages and research firms:

  • 8/9/2017 – Gilead Sciences was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 8/2/2017 – Gilead Sciences was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 7/28/2017 – Gilead Sciences was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $84.00 price target on the stock. According to Zacks, “Gilead reported better-than-expected results for the second quarter driven by positive trends in the non-HCV business and improved results from HCV business due to rapid uptake of Epclusa. The HCV franchise was boosted by the FDA approval of Vosevi. HCV patient starts in the first half were better than expectations but should see a gradual decline in the second half due to increased competition. Meanwhile, the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens in the U.S. and EU, which now represent 51% of total prescription volume. Genvoya is now the company’s bestselling HIV product with a treatment-naïve patient share of 41%. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should further boost sales. However, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which will impact sales. Shares of the company have underperformed the industry.”
  • 7/27/2017 – Gilead Sciences had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $90.00 price target on the stock.
  • 7/27/2017 – Gilead Sciences had its “hold” rating reaffirmed by analysts at Maxim Group.
  • 7/27/2017 – Gilead Sciences had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $83.00 price target on the stock.
  • 7/27/2017 – Gilead Sciences had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $81.00 price target on the stock, up previously from $79.00.
  • 7/27/2017 – Gilead Sciences was given a new $85.00 price target on by analysts at J P Morgan Chase & Co. They now have an “overweight” rating on the stock.
  • 7/27/2017 – Gilead Sciences had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $82.00 price target on the stock, up previously from $72.00.
  • 7/26/2017 – Gilead Sciences is now covered by analysts at Redburn Partners. They set a “buy” rating on the stock.
  • 7/25/2017 – Gilead Sciences had its “hold” rating reaffirmed by analysts at Leerink Swann. They now have a $74.00 price target on the stock.
  • 7/25/2017 – Gilead Sciences had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $87.00 price target on the stock.
  • 7/24/2017 – Gilead Sciences was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 7/21/2017 – Gilead Sciences had its “hold” rating reaffirmed by analysts at BMO Capital Markets. They now have a $72.00 price target on the stock.
  • 7/18/2017 – Gilead Sciences was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Gilead’s HIV franchise has been gaining momentum of late. Rapid adoption of TAF-based regimens, representing 42% of total Gilead HIV prescription volume, following the launch of Genvoya and the launches of Odefsey and Descovy in 2016 boosted results. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales.The company saw a significant uptick in PrEP usage in 2017 with an estimated 125,000 patients using Truvada by the end of the first quarter. The company submitted a NDA to the FDA for single tablet regimen for bictegravir. However, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which should impact sales. In addition, the HCV franchise continues to be under competitive and pricing pressure leading to a decline in Harvoni and Sovaldi sales.”
  • 7/17/2017 – Gilead Sciences was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $79.00 price target on the stock. According to Zacks, “Gilead’s HIV franchise has been gaining momentum of late. Rapid adoption of TAF-based regimens, representing 42% of total Gilead HIV prescription volume, following the launch of Genvoya and the launches of Odefsey and Descovy in 2016 boosted results. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales.The company saw a significant uptick in PrEP usage in 2017 with an estimated 125,000 patients using Truvada by the end of the first quarter. The company submitted a NDA to the FDA for single tablet regimen for bictegravir. However, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which should impact sales. In addition, the HCV franchise continues to be under competitive and pricing pressure leading to a decline in Harvoni and Sovaldi sales.”
  • 7/13/2017 – Gilead Sciences had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $87.00 price target on the stock.
  • 7/11/2017 – Gilead Sciences had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $80.00 price target on the stock.
  • 7/11/2017 – Gilead Sciences had its “equal weight” rating reaffirmed by analysts at Morgan Stanley.
  • 7/5/2017 – Gilead Sciences had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $90.00 price target on the stock.
  • 7/4/2017 – Gilead Sciences had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $82.00 price target on the stock.
  • 7/4/2017 – Gilead Sciences had its “overweight” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a $82.00 price target on the stock.
  • 6/26/2017 – Gilead Sciences was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $83.66 price target on the stock.
  • 6/23/2017 – Gilead Sciences is now covered by analysts at Deutsche Bank AG. They set a “buy” rating and a $79.00 price target on the stock.
  • 6/22/2017 – Gilead Sciences was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 6/22/2017 – Gilead Sciences had its “market perform” rating reaffirmed by analysts at Leerink Swann.
  • 6/21/2017 – Gilead Sciences was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $75.40 price target on the stock.
  • 6/16/2017 – Gilead Sciences had its “outperform” rating reaffirmed by analysts at William Blair.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded down 1.62% during mid-day trading on Thursday, hitting $72.70. 8,812,369 shares of the company’s stock traded hands. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $82.10. The stock has a market cap of $94.94 billion, a P/E ratio of 7.90 and a beta of 1.21. The stock has a 50 day moving average price of $72.16 and a 200-day moving average price of $68.73.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business’s revenue was down 8.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.08 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post $8.76 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.86%. Gilead Sciences’s dividend payout ratio is currently 22.58%.

In other news, EVP Gregg H. Alton sold 40,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $74.00, for a total value of $2,960,000.00. Following the transaction, the executive vice president now owns 137,488 shares of the company’s stock, valued at approximately $10,174,112. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total transaction of $355,300.00. Following the completion of the transaction, the executive vice president now directly owns 102,988 shares in the company, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. Insiders sold a total of 206,666 shares of company stock worth $15,223,184 in the last ninety days. Corporate insiders own 1.30% of the company’s stock.

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Receive News & Ratings for Gilead Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.